Hyaluronic acid (HA) injections are widely used worldwide for the treatment of osteoarthritis and other joint-related conditions. For importers and hospitals, choosing the right supplier is crucial—not only for ensuring patient safety but also for maintaining operational efficiency. This article outlines what buyers should carefully evaluate before purchasing HA injections and highlights why Orthosyn Medikal is a reliable partner in this field.
The first factor that importers and hospitals must examine is regulatory compliance. Hyaluronic acid injections must meet internationally recognized safety and quality standards.
CE Certification: Orthosyn Medikal’s HA injections are CE certified, which makes them fully compliant with European medical device directives.
FDA vs. CE: While FDA approval is essential for the U.S. market, in most regions worldwide—including Europe, Asia, the Middle East, Africa, and Latin America—CE certification is widely accepted as sufficient for registration and commercialization.
This ensures that Orthosyn Medikal’s injections are positioned to enter multiple markets seamlessly.
Hospitals and distributors should evaluate whether the supplier offers a diverse portfolio that meets different clinical needs.
Orthosyn Medikal provides a broad selection of HA formulations:
Cross-linked Injections: 72 mg, 90 mg
Non-cross-linked Injections: 32 mg, 48 mg
This variety allows physicians to choose the right formulation based on the severity of osteoarthritis, patient profile, and desired duration of therapeutic effect.
One of the biggest concerns for hospitals and distributors is supply continuity. Stock shortages can delay treatments and reduce patient satisfaction.
Orthosyn Medikal stands out with its high stock capacity and rapid delivery commitment:
Orders up to 500 units (for 72 mg, 90 mg cross-linked and 32 mg, 48 mg non-cross-linked products) are shipped within 1–3 business days.
Larger custom orders are prepared within 1–15 business days, depending on the quantity.
This ensures uninterrupted supply for hospitals and smooth distribution for importers.
Numerous clinical studies confirm that HA injections improve joint lubrication, reduce pain, and enhance mobility in patients with osteoarthritis. Cross-linked formulations often provide longer-lasting relief, while non-cross-linked options are ideal for early-stage cases or patients requiring more frequent but lighter therapy.
By offering both types, Orthosyn Medikal allows hospitals to tailor treatment options for a wide spectrum of patients.
CE Certified Quality: Safe and compliant for international markets.
Wide Portfolio: Both cross-linked and non-cross-linked formulations.
High Stock Capacity: Fast shipping within 1–3 days for up to 500 units.
Trusted Partner: Focused on reliability, regulatory support, and sustainable supply.
For hospitals and distributors, choosing the right hyaluronic acid injection supplier means balancing regulatory compliance, product diversity, and supply chain reliability. With CE-certified products, broad formulation options, and a strong stock infrastructure, Orthosyn Medikal is a strategic partner for importers and healthcare institutions seeking safe, effective, and readily available HA injections.